AEON Profile
AEON Biopharma, Inc. is a biopharmaceutical firm dedicated to the development and commercialization of therapeutic botulinum toxins aimed at treating severe medical conditions. The company is pioneering the application of its flagship product, ABP-450, a 900 kDa botulinum toxin complex, targeting the management of chronic migraines, cervical dystonia, and gastroparesis. AEON Biopharma's innovative approach seeks to leverage the unique properties of botulinum toxins to provide effective, long-lasting relief for patients suffering from these debilitating disorders.
Originally founded as ALPHAEON Corporation in 2012, the company underwent a rebranding to AEON Biopharma, Inc. in December 2019, reflecting its renewed focus on biopharmaceutical advancements. Based in Newport Beach, California, AEON Biopharma operates at the nexus of medical research and clinical application, striving to develop novel treatments that address significant unmet medical needs. The company’s mission is to improve patient outcomes through targeted therapies that harness the therapeutic potential of botulinum toxin.
AEON Biopharma's development pipeline is centered around ABP-450, which is undergoing rigorous clinical trials to establish its efficacy and safety profile across multiple indications. For chronic migraines, ABP-450 aims to provide a new therapeutic option for patients who have not responded adequately to existing treatments. In the case of cervical dystonia, the product is being investigated for its ability to alleviate muscle spasms and pain, enhancing patients’ quality of life. For gastroparesis, a condition characterized by delayed gastric emptying, ABP-450 holds promise as a treatment to improve gastrointestinal motility and symptom management.
The company’s leadership team comprises experienced professionals with a deep understanding of neurology, gastroenterology, and clinical development. Their combined expertise supports AEON Biopharma’s commitment to advancing its product pipeline and bringing innovative therapies to market. By focusing on high-impact medical conditions and leveraging cutting-edge biopharmaceutical technologies, AEON Biopharma aspires to make a significant impact on global healthcare and establish itself as a leader in the therapeutic botulinum toxin space.
|
